Moreover, in this study, TNXB was detected in the serum samples of all patients diagnosed with benign breast diseases and LN-negative cancer patients, but not in LN-positive patients, indicating that loss of circulating TNXB could be used as a biomarker of LN metastasis [108]. Here, TNXB is linked to breast fibrocystic disease.